Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

How long COVID survivors are revolutionizing health care

Written by | 29 Mar 2024

To the world’s public health authorities, Covid-19 would be either a deadly disease for some or a simple respiratory illness for most, its symptoms clearing up in just… read more.

Positive topline results from phase II study evaluating Ampligen (rinatatolimod) for the treatment of post-COVID conditions – AIM ImmunoTech Inc

Written by | 18 Feb 2024

AIM ImmunoTech Inc. announced positive topline results from the Company’s Phase II study evaluating the efficacy and safety of Ampligen as a potential therapeutic for people with the… read more.

Ten per cent treatment boost needed to shift NHS Covid backlog

Written by | 21 Jan 2024

The NHS must treat at least 10 per cent more non-emergency hospital cases a month if it is to successfully start reducing the hefty backlog caused by the… read more.

France recorded ‘post-COVID’ surge in meningococcal disease

Written by | 13 Jan 2024

An unprecedented resurgence in invasive meningococcal disease followed the lifting of pandemic restrictions in France, according to a paper published in the Journal of Infection and Public Health… read more.

‘Long flu’ has emerged as a consequence similar to long COVID

Written by | 21 Dec 2023

Since the COVID-19 pandemic began, extensive research has emerged detailing the virus’s ability to attack multiple organ systems, potentially resulting in a set of enduring and often disabling… read more.

Final results for VV116 (mindeudesivir hydrobromide) shows efficacy in COVID 19 trial – Junishi Biosciences

Written by | 2 Dec 2023

Junshi Biosciences has revealed the final results for its Covid-19 pill VV 116 (mindeudesivir hydrobromide), indicating its efficacy. The data, which was published in The Lancet Infectious Diseases… read more.

Virologic rebound in Covid-19 is higher than expected among Paxlovid patients

Written by | 16 Nov 2023

Researchers from a study of patients treated for acute COVID-19 report that virologic rebound takes place in about 20.8 percent of subjects treated with nirmatrelvir-ritonavir (N-R, Paxlovid) versus… read more.

Survey finds many Americans are letting their guard down during respiratory illness season

Written by | 12 Nov 2023

Despite the Centers for Disease Control and Prevention warning this year will be potentially dangerous for respiratory illnesses, a third of Americans are not concerned about the threat,… read more.

Financial insecurity common among frontline healthcare workers during COVID-19

Written by | 30 Oct 2023

Many frontline health care workers in the United States experienced food insecurity and other significant financial challenges during the COVID-19 pandemic, according to a recent study led by… read more.

Covid conspiracies: social media fatigue linked to misinformation

Written by | 21 Oct 2023

The spread of false information and conspiracy theories accelerated during the peak of the COVID-19 pandemic. Inadvertently inaccurate, and some deliberately misleading, ideas were widely shared on social… read more.

New research finds greater continuity of psychotherapy after shift to telehealth

Written by | 14 Oct 2023

The rapid transition to virtual care that occurred with the onset of the COVID-19 pandemic resulted in better continuity of psychotherapy visits compared to prior to the pandemic… read more.

Contagious omicron strain replicates early in infection

Written by | 26 Sep 2023

New research used engineered mice to compare SARS-COV-2 omicron subvariants and found one of them – BA.5 – was more virulent likely due to its ability to rapidly… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.